Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CMPX Compass Therapeutics	$3.49	$2.93	$1.25 ▼ $4.08	$482.61M	1.49	1.47 million shs	702,510 shs
CRVS Corvus Pharmaceuticals	$5.74 +6.1%	$4.52	$2.54 ▼ $10.00	$403.12M	0.42	521,085 shs	557,521 shs
IMAB I-Mab	$4.16 -2.1%	$3.03	$0.60 ▼ $5.90	$347.06M	1.38	4.86 million shs	1.40 million shs
MGNX MacroGenics	$1.77 +4.1%	$1.54	$0.99 ▼ $5.10	$107.45M	1.65	599,170 shs	854,040 shs

Ten Starter Stocks For Beginners to Buy Now

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CMPX Compass Therapeutics	0.00%	+15.56%	+14.43%	+63.08%	+193.28%
CRVS Corvus Pharmaceuticals	+6.10%	+3.42%	+31.05%	+51.05%	+40.00%
IMAB I-Mab	-2.12%	-18.27%	+104.93%	+220.00%	+255.56%
MGNX MacroGenics	+4.12%	+4.73%	+14.94%	+29.10%	-48.70%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CMPX Compass Therapeutics	2.1759 of 5 stars	3.6	1.0	0.0	2.2	3.3	0.0
CRVS Corvus Pharmaceuticals	3.1735 of 5 stars	3.5	2.0	0.0	3.7	3.3	0.6
IMAB I-Mab	2.957 of 5 stars	3.5	5.0	0.0	2.8	1.7	0.0
MGNX MacroGenics	4.2159 of 5 stars	3.3	3.0	4.4	2.2	4.2	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CMPX Compass Therapeutics	3.10	Buy	$12.89	269.31% Upside
CRVS Corvus Pharmaceuticals	3.00	Buy	$15.00	161.32% Upside
IMAB I-Mab	3.00	Buy	$7.00	68.27% Upside
MGNX MacroGenics	2.57	Moderate Buy	$3.60	103.39% Upside

Current Analyst Ratings Breakdown

Latest MGNX, CMPX, IMAB, and CRVS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/28/2025	IMAB I-Mab	Loop Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$8.00
8/28/2025	IMAB I-Mab	Brookline Capital Management Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
8/21/2025	IMAB I-Mab	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$7.00
8/20/2025	IMAB I-Mab	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$5.00 ➝ $6.00
8/15/2025	MGNX MacroGenics	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$8.00 ➝ $5.00
8/12/2025	CMPX Compass Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$32.00
8/12/2025	CMPX Compass Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$10.00 ➝ $12.00
7/9/2025	IMAB I-Mab	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00
7/9/2025	IMAB I-Mab	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$7.00
7/1/2025	CMPX Compass Therapeutics	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Outperform	$9.00
6/27/2025	IMAB I-Mab	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$4.00 ➝ $5.00

(Data available from 8/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CMPX Compass Therapeutics	N/A	N/A	N/A	N/A	$0.67 per share	N/A
CRVS Corvus Pharmaceuticals	N/A	N/A	N/A	N/A	$1.08 per share	N/A
IMAB I-Mab	$3.89M	87.33	N/A	N/A	$2.41 per share	1.73
MGNX MacroGenics	$163.87M	0.68	N/A	N/A	$0.74 per share	2.39

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CMPX Compass Therapeutics	-$49.38M	-$0.45	N/A	N/A	N/A	N/A	-53.11%	-46.14%	11/11/2025 (Estimated)
CRVS Corvus Pharmaceuticals	-$62.29M	-$1.01	N/A	N/A	N/A	N/A	-28.61%	-18.05%	11/11/2025 (Estimated)
IMAB I-Mab	-$22.23M	N/A	0.00	N/A	N/A	N/A	-19.65%	-18.58%	11/13/2025 (Estimated)
MGNX MacroGenics	-$66.97M	-$0.57	N/A	N/A	N/A	-21.99%	-40.24%	-14.62%	11/4/2025 (Estimated)

Latest MGNX, CMPX, IMAB, and CRVS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/20/2025	Q2 2025	IMAB I-Mab	-$0.10	-$0.07	+$0.03	-$0.07	N/A	N/A
8/14/2025	Q2 2025	MGNX MacroGenics	-$0.59	-$0.57	+$0.02	-$0.57	$28.06 million	$22.24 million
8/11/2025	Q2 2025	CMPX Compass Therapeutics	-$0.13	-$0.14	-$0.01	-$0.14	N/A	N/A
8/7/2025	Q2 2025	CRVS Corvus Pharmaceuticals	-$0.13	-$0.10	+$0.03	-$0.10	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CMPX Compass Therapeutics	N/A	N/A	N/A	N/A	N/A
CRVS Corvus Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
IMAB I-Mab	N/A	N/A	N/A	N/A	N/A
MGNX MacroGenics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CMPX Compass Therapeutics	N/A	7.66	7.66
CRVS Corvus Pharmaceuticals	N/A	8.91	8.91
IMAB I-Mab	N/A	22.82	22.82
MGNX MacroGenics	N/A	5.26	5.02

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CMPX Compass Therapeutics	68.43%
CRVS Corvus Pharmaceuticals	46.64%
IMAB I-Mab	38.38%
MGNX MacroGenics	96.89%

Insider Ownership

Company	Insider Ownership
CMPX Compass Therapeutics	29.80%
CRVS Corvus Pharmaceuticals	28.50%
IMAB I-Mab	22.10%
MGNX MacroGenics	13.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CMPX Compass Therapeutics	20	138.28 million	97.08 million	Not Optionable
CRVS Corvus Pharmaceuticals	30	74.51 million	53.28 million	Optionable
IMAB I-Mab	380	81.66 million	63.61 million	Optionable
MGNX MacroGenics	430	63.21 million	54.99 million	Optionable

MGNX, CMPX, IMAB, and CRVS Headlines

Recent News About These Companies

MacroGenics (NASDAQ:MGNX) Stock Price Crosses Below 200 Day Moving Average - Should You Sell?

August 28 at 4:18 AM | marketbeat.com

William Heiden Bought 909% More Shares In MacroGenics

August 23, 2025 | finance.yahoo.com

William Heiden Bought 909% More Shares In MacroGenics

August 23, 2025 | finance.yahoo.com

Stifel Nicolaus Keeps Their Hold Rating on MacroGenics (MGNX)

August 23, 2025 | theglobeandmail.com

MacroGenics (NASDAQ:MGNX) Director William Heiden Acquires 49,500 Shares

August 22, 2025 | insidertrades.com

MacroGenics, Inc. (NASDAQ:MGNX) Receives $3.60 Consensus PT from Analysts

August 21, 2025 | americanbankingnews.com

MacroGenics, Inc. (NASDAQ:MGNX) Receives Average Recommendation of "Moderate Buy" from Analysts

August 19, 2025 | marketbeat.com

Citizens JMP Keeps Their Hold Rating on MacroGenics (MGNX)

August 17, 2025 | theglobeandmail.com

MacroGenics (NASDAQ:MGNX) Posts Quarterly Earnings Results, Beats Estimates By $0.02 EPS

August 17, 2025 | marketbeat.com

Leerink Partners Lowers MacroGenics (NASDAQ:MGNX) Price Target to $5.00

August 17, 2025 | marketbeat.com

MacroGenics Reports Second Quarter 2025 Financial Results and Highlights Key Strategic Priorities

August 16, 2025 | uk.finance.yahoo.com

MacroGenics Revenue Doubles in Q2

August 16, 2025 | theglobeandmail.com

MacroGenics price target lowered to $5 from $8 at Leerink

August 16, 2025 | msn.com

MacroGenics (NASDAQ:MGNX) Stock Crosses Below Two Hundred Day Moving Average - Here's Why

August 15, 2025 | marketbeat.com

MacroGenics Inc. Reports Q2 2025 Financial Results

August 15, 2025 | msn.com

MacroGenics reports Q2 EPS (57c), consensus (38c)

August 14, 2025 | msn.com

MacroGenics (MGNX) Reports Q2 Loss, Tops Revenue Estimates

August 14, 2025 | zacks.com

MacroGenics: Q2 Earnings Snapshot

August 14, 2025 | timesunion.comT

MacroGenics Reports Second Quarter 2025 Financial Results and Highlights Key Strategic Priorities

August 14, 2025 | globenewswire.com

MacroGenics, Inc.: MacroGenics Appoints Eric Risser as President and Chief Executive Officer

August 14, 2025 | finanznachrichten.de

MacroGenics CEO Scott Koenig steps down, Eric Risser succeeds

August 14, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

MGNX, CMPX, IMAB, and CRVS Company Descriptions

Compass Therapeutics NASDAQ:CMPX

$3.49 0.00 (0.00%)

Closing price 08/29/2025 04:00 PM Eastern

Extended Trading

$3.52 +0.03 (+1.00%)

As of 08/29/2025 07:27 PM Eastern

Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells. It also develops CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1 checkpoint inhibitor antibodies. The company was founded in 2014 and is headquartered in Boston, Massachusetts.

Corvus Pharmaceuticals NASDAQ:CRVS

$5.74 +0.33 (+6.10%)

Closing price 08/29/2025 04:00 PM Eastern

Extended Trading

$5.68 -0.06 (-1.05%)

As of 08/29/2025 07:44 PM Eastern

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.

I-Mab NASDAQ:IMAB

$4.16 -0.09 (-2.12%)

Closing price 08/29/2025 04:00 PM Eastern

Extended Trading

$4.24 +0.08 (+1.80%)

As of 08/29/2025 07:27 PM Eastern

I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics in the fields of immuno-oncology and immuno-inflammation diseases primarily in the United States. It is developing Uliledlimab, a CD73 neutralizing antibody, which is in Phase 2 clinical trial for the treatment of solid tumors; Givastomig, a bi-specific antibody that is in Phase 1 clinical trial for the treatment of gastric and other cancers; and Ragistomig, a programmed cell death ligand-based tumor-dependent T cell engager, which is in Phase 1 clinical trial for the treatment of for solid tumors. The company is also evaluating opportunities to develop Lemzoparlimab, a fully human CD47 monoclonal antibody for cancer immunotherapy. It has strategic licensing agreement with Ferring International Center SA to research, develop, make, have made, import, use, sell and offer to sell FE301, an interleukin-6 inhibitor. The company has clinical collaboration with Bristol Myers Squibb to evaluate Claudin 18.2 x 4-1BB bispecific antibody givastomig in combination with nivolumab and chemotherapy for the treatment of gastric and esophageal cancer. I-Mab was founded in 2014 and is headquartered in Rockville, Maryland.

MacroGenics NASDAQ:MGNX

$1.77 +0.07 (+4.12%)

Closing price 08/29/2025 04:00 PM Eastern

Extended Trading

$1.76 -0.01 (-0.51%)

As of 08/29/2025 07:56 PM Eastern

MacroGenics, Inc., a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. In addition, it develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3; Retifanlimab, a humanized monoclonal antibody targeting programmed death receptor-1; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time